| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/JVI.02061-10 |
| P8608 | Fatcat ID | release_7vvp3uugnzfz7mkscsnpv5okke |
| P932 | PMC publication ID | 3067800 |
| P698 | PubMed publication ID | 21177825 |
| P2093 | author name string | Hong Chen | |
| Jacqueline Muller | |||
| Yamei Gao | |||
| Yisheng Ni | |||
| Konstantin Virnik | |||
| Angelo Spadaccini | |||
| Danah Al-Awadi | |||
| Dino Feigelstock | |||
| Ira Berkower | |||
| P2860 | cites work | Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies | Q24561905 |
| Hepatitis B virus morphogenesis | Q24563883 | ||
| Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes | Q27469889 | ||
| Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins | Q27472616 | ||
| HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane | Q27649531 | ||
| Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41 | Q28236154 | ||
| Distribution and three-dimensional structure of AIDS virus envelope spikes | Q29617562 | ||
| Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes | Q29619514 | ||
| Membrane protein folding: beyond the two stage model. | Q30336254 | ||
| Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. | Q31016954 | ||
| An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10 | Q33272711 | ||
| Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance | Q33591736 | ||
| Helical membrane protein folding, stability, and evolution | Q34019415 | ||
| Expression of hepatitis B surface antigen gene in yeast | Q34055398 | ||
| A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 | Q34306804 | ||
| Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope | Q34348303 | ||
| Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. | Q35700066 | ||
| The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design | Q36497712 | ||
| Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment | Q36531845 | ||
| An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1 | Q36687524 | ||
| Mutational analysis of hepatitis B surface antigen particle assembly and secretion | Q36701575 | ||
| Expression and characterization of hepatitis B virus surface antigen polypeptides in insect cells with a baculovirus expression system | Q36791418 | ||
| Targeted deletion in the beta20-beta21 loop of HIV envelope glycoprotein gp120 exposes the CD4 binding site for antibody binding | Q37179763 | ||
| Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles | Q37251390 | ||
| Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic | Q37353496 | ||
| The role of envelope proteins in hepatitis B virus assembly | Q37393563 | ||
| The first transmembrane domain of the hepatitis B virus large envelope protein is crucial for infectivity | Q37410736 | ||
| Phenotypic mixing of rodent but not avian hepadnavirus surface proteins into human hepatitis B virus particles | Q39868858 | ||
| Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies | Q39947897 | ||
| Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in Escherichia coli. | Q40046366 | ||
| Hepatitis B virus subviral envelope particle morphogenesis and intracellular trafficking | Q40176615 | ||
| A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. | Q40757568 | ||
| Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. | Q41171978 | ||
| A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. | Q41419602 | ||
| Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment | Q42039880 | ||
| Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies. | Q42986799 | ||
| Trimeric membrane-anchored gp41 inhibits HIV membrane fusion. | Q43932246 | ||
| A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group | Q44174498 | ||
| Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins | Q45600915 | ||
| Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission | Q45839365 | ||
| Cellular and Humoral Immunity in Guinea Pigs to Two Major Polypeptides Derived from Hepatitis B Surface Antigen | Q46814768 | ||
| A topological model for hepatitis B surface antigen | Q47637820 | ||
| Identification of a BRCA1-associated kinase with potential biological relevance. | Q52562470 | ||
| Human hepatitis B vaccine from recombinant yeast | Q52850114 | ||
| A new WHO International Reference Reagent for use in potency assays of inactivated poliomyelitis vaccine. | Q53361176 | ||
| Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines | Q67972576 | ||
| Targeting murine immune responses to selected T cell- or antibody-defined determinants of the hepatitis B surface antigen by plasmid DNA vaccines encoding chimeric antigen | Q73365903 | ||
| Effect of the contents and form of rabies glycoprotein on the potency of rabies vaccination in cattle | Q74119235 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Hepatitis B virus | Q6844 |
| transmembrane protein | Q424204 | ||
| P304 | page(s) | 2439-2448 | |
| P577 | publication date | 2010-12-22 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Hepatitis B virus surface antigen assembly function persists when entire transmembrane domains 1 and 3 are replaced by a heterologous transmembrane sequence | |
| P478 | volume | 85 |
| Q64115548 | 3D visualisation of hepatitis B vaccine in the oral delivery vehicle SBA-15 |
| Q64445308 | Extracellular RNA in viral–host interactions: Thinking outside the cell |
| Q38042329 | Host factors involved in hepatitis B virus maturation, assembly, and egress. |
| Q42284964 | Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers |
| Q90086208 | Occult HBV infection in Chinese blood donors: role of N-glycosylation mutations and amino acid substitutions in S protein transmembrane domains |
| Q37505405 | Prospects for prophylactic hepatitis C vaccines based on virus-like particles |
| Q39244709 | Role of transmembrane domains of hepatitis B virus small surface proteins in subviral-particle biogenesis |
| Q28730718 | Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine |
Search more.